Source: Dermatology Times LEO Pharma announced today its acquisition of Timber Pharmaceuticals, a transaction valued at $36 million.1 Timber Pharmaceuticals has been evaluating the safety and efficacy of its breakthrough therapy, TMB-001, for the treatment of congenital ichthyosis (CI). TMB-001, a topical isotretinoin formulation, was granted Fast Track Designation in April 2022 and Breakthrough Therapy…...